Fesoterodine
- Generic Name
- Fesoterodine
- Brand Names
- Toviaz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37NO3
- CAS Number
- 286930-02-7
- Unique Ingredient Identifier
- 621G617227
- Background
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
- Indication
适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
FDA Approves Gemtesa (Vibegron) for Overactive Bladder in Men with BPH
• The FDA has approved Gemtesa (vibegron) for men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH).
• Gemtesa is the first and only beta-3 adrenergic receptor agonist approved for OAB in men being treated for BPH, addressing a significant unmet need.
• Approval was based on a Phase 3 trial demonstrating significant reductions in micturition and urgency episodes compared to placebo.
• Common adverse reactions in the trial included hypertension and urinary tract infections, with a similar rate of serious adverse events to placebo.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath